Clene Presented New Long-term CNM-AU8 Treatment Results For Survival And Neurofilament Light Levels From HEALEY ALS Platform Trial Open Label Extension At The European Network For The Cure Of ALS Meeting
Portfolio Pulse from Benzinga Newsdesk
Clene presented new long-term results for its CNM-Au8 treatment at the European Network for the Cure of ALS meeting, showing improved survival and reduced neurofilament light levels in ALS patients.
June 18, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene presented positive long-term results for its CNM-Au8 treatment, showing improved survival and reduced neurofilament light levels in ALS patients, with no safety signals identified.
The positive long-term results for CNM-Au8, including improved survival and reduced neurofilament light levels, are likely to boost investor confidence in Clene. The absence of safety signals further strengthens the case for the treatment's efficacy and safety, potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100